Skip to main
OMER
OMER logo

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros Corp has demonstrated a positive financial trajectory, evidenced by an increase in other income to $2.1 million due to higher interest income from its larger cash balance, which supports ongoing operations and growth. The company is also preparing for the End-of-Phase 2 submission for its lead candidate narsoplimab, having shown a statistically significant survival advantage for treated patients, bolstering the clinical evidence for its development in complement-mediated diseases. Furthermore, Omeros is focusing on late-stage development planning amidst a competitive landscape for complement-targeting therapies, highlighting its commitment to advancing potentially transformative treatments in areas with significant unmet medical needs.

Bears say

Omeros Corporation has incurred substantial operating losses, with expectations of remaining unprofitable for several years, indicating significant financial instability. The company's recent decrease in research and development expenses, reflective of a reduction in clinical trials, suggests a cautionary approach as it faces challenges in funding and operational capabilities. There are concerns regarding the likelihood of FDA approval for narsoplimab, driven by an atypical development trajectory, insufficient clinical data, and a prolonged period without new clinical evidence since the Complete Response Letter (CRL).

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.